Entela Xoxi

479 total citations
20 papers, 370 citations indexed

About

Entela Xoxi is a scholar working on Economics and Econometrics, Molecular Biology and Physiology. According to data from OpenAlex, Entela Xoxi has authored 20 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 4 papers in Molecular Biology and 4 papers in Physiology. Recurrent topics in Entela Xoxi's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (10 papers) and Biomedical Ethics and Regulation (3 papers). Entela Xoxi is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (10 papers) and Biomedical Ethics and Regulation (3 papers). Entela Xoxi collaborates with scholars based in Italy, United Kingdom and Netherlands. Entela Xoxi's co-authors include Americo Cicchetti, P.D. Siviero, Luciano Saso, Thomas Morel, Steven Simoens, Francis Arickx, Luca Pani, Karen Facey, F. I. Javier Pastor and Pilar Dı́az and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Environmental Research and Public Health and Clinical Pharmacology & Therapeutics.

In The Last Decade

Entela Xoxi

19 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Entela Xoxi Italy	10	222	68	43	36	34	20	370
Michael Lanthier United States	9	213 1.0×	82 1.2×	73 1.7×	25 0.7×	75 2.2×	12	448
Christopher‐Paul Milne United States	11	137 0.6×	44 0.6×	112 2.6×	37 1.0×	28 0.8×	34	378
Lawrence Liberti United Kingdom	15	405 1.8×	58 0.9×	49 1.1×	68 1.9×	36 1.1×	43	587
Roberta Joppi Italy	10	326 1.5×	24 0.4×	101 2.3×	23 0.6×	21 0.6×	20	451
Zaheer Uddin Babar United Kingdom	10	155 0.7×	43 0.6×	55 1.3×	20 0.6×	7 0.2×	16	345
Alexander C. Egilman United States	10	164 0.7×	19 0.3×	33 0.8×	37 1.0×	24 0.7×	22	290
Audrey D. Zhang United States	10	145 0.7×	36 0.5×	32 0.7×	49 1.4×	17 0.5×	19	291
Joris Langedijk Netherlands	5	61 0.3×	105 1.5×	73 1.7×	19 0.5×	20 0.6×	5	321
Marisa Papaluca‐Amati Netherlands	10	75 0.3×	53 0.8×	62 1.4×	50 1.4×	47 1.4×	11	395
Ronald P. Evens United States	10	34 0.2×	45 0.7×	64 1.5×	19 0.5×	22 0.6×	29	305

Countries citing papers authored by Entela Xoxi

Since Specialization

Citations

This map shows the geographic impact of Entela Xoxi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Entela Xoxi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Entela Xoxi more than expected).

Fields of papers citing papers by Entela Xoxi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Entela Xoxi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Entela Xoxi. The network helps show where Entela Xoxi may publish in the future.

Co-authorship network of co-authors of Entela Xoxi

This figure shows the co-authorship network connecting the top 25 collaborators of Entela Xoxi. A scholar is included among the top collaborators of Entela Xoxi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Entela Xoxi. Entela Xoxi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Gayathri S., Amanda Cole, Lieven Annemans, et al.. (2024). Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens. The Oncologist. 29(6). 465–472.

Maifredi, Giovanni, et al.. (2024). The Hospital Burden of Flu in Italy: a retrospective study on administrative data from season 2014–2015 to 2018–2019. BMC Infectious Diseases. 24(1). 572–572. 2 indexed citations

Kaló, Zoltán, Maciej Niewada, Wim Goettsch, et al.. (2023). Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries. Expert Review of Pharmacoeconomics & Outcomes Research. 24(2). 181–187. 1 indexed citations

Xoxi, Entela, et al.. (2022). Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies. SHILAP Revista de lepidopterología. 4. 917151–917151. 5 indexed citations

Xoxi, Entela, et al.. (2022). A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. SHILAP Revista de lepidopterología. 4. 888404–888404. 16 indexed citations

Armeni, Patrizio, Marianna Cavazza, Entela Xoxi, Domenica Taruscio, & Yllka Kodra. (2021). Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. International Journal of Environmental Research and Public Health. 18(3). 1101–1101. 9 indexed citations

Facey, Karen, Jaime Espín, E. Kent, et al.. (2021). Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. PharmacoEconomics. 39(9). 1021–1044. 35 indexed citations

Xoxi, Entela, Karen Facey, & Americo Cicchetti. (2021). The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. Frontiers in Pharmacology. 12. 699466–699466. 29 indexed citations

Cicchetti, Americo, et al.. (2020). PP469 From Theory To Practice: Which Value Framework Is Applied For Onco-Hematology Therapies In Italy? A 5-year Retrospective Analysis. International Journal of Technology Assessment in Health Care. 36(S1). 37–37. 1 indexed citations

10.

Bouvy, Jacoline C., Páll Jónsson, Antonella Santuccione Chadha, et al.. (2018). Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease. CNS Drugs. 32(12). 1085–1090. 4 indexed citations

11.

Chassang, Sylvain, Valentina Mantua, Erik Snowberg, Entela Xoxi, & Luca Pani. (2018). Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties. SSRN Electronic Journal. 2 indexed citations

12.

Longo, Antonio, Alessandra Casuccio, Luca Pani, et al.. (2016). Association of neovascular age-related macular degeneration with month and season of birth in Italy. Aging. 9(1). 133–141. 5 indexed citations

13.

Lee, Michael, Danchen Qin, Entela Xoxi, et al.. (2016). Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. Clinical Pharmacology & Therapeutics. 100(6). 730–742. 20 indexed citations

14.

Montilla, Simona, Entela Xoxi, Pierluigi Russo, Americo Cicchetti, & Luca Pani. (2015). MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. International Journal of Technology Assessment in Health Care. 31(4). 210–213. 36 indexed citations

15.

Morel, Thomas, et al.. (2013). Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet Journal of Rare Diseases. 8(1). 198–198. 94 indexed citations

16.

Morel, Thomas, et al.. (2013). Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012). Value in Health. 16(7). A391–A391. 4 indexed citations

17.

Xoxi, Entela, et al.. (2012). The Italian post-marketing registries. 5(1-2). 57–60. 12 indexed citations

18.

Ruiz, Cristian, Entela Xoxi, Giovanni Nicolosi, et al.. (2006). Inhibition of Candida rugosa lipase by saponins, flavonoids and alkaloids. Journal of Molecular Catalysis B Enzymatic. 40(3-4). 138–143. 32 indexed citations

19.

Dimitrova, Petya, et al.. (2005). Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections. Journal of Medical Microbiology. 54(7). 647–653. 14 indexed citations

20.

Ruiz, Cristian, et al.. (2004). Activation and inhibition of Candida rugosa and Bacillus-related lipases by saturated fatty acids, evaluated by a new colorimetric microassay. Biochimica et Biophysica Acta (BBA) - General Subjects. 1672(3). 184–191. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact